Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by MrMonkon Oct 29, 2012 2:06pm
281 Views
Post# 20535878

Update

Update

I've leared that ARZ doe NOT officially need to pony up the remaining $9 million (Phase 3) until the final day of the final phase (around May or June of 2013 if I'm not mistaken).  ARZ is dealing with some of its own issues right now – it has forecasted 150,000 ounces of production this year and is roughly 10,000 ounces behind on production.  If it misses the 150K target, the stock won't fare well.  So it's focusing itsresources on getting back on track to reach 150K ounces this year.  Otherwise, ARZ is very pleaed with NOX and Marban.  Funny, if ARZ did not proceed with Phase 3 (highly unlikely), that won’t be so bad for NOX – they’ll have been gifted $11 million in exploration dollars (already spent – you can see the return on that - $2.1 million ounces and counting) and they’d still own 100% of the project! 

Also, with respect to the last 43-101, ARZ chose the third-party that handled it and the highly conservative approach used probably cost NOX another 600,000 ounces (30%).  Add in perhapsanother 400,000 ounces from Phase 2 (NOT included in the last 43-101 update), and NOX is over 3 million ounces – that’s a lot of gold at $1,700.00 per ounce. 

NOX has some of its own news coming out soon.  It’s unfortunate the stock has gotten hit like many of the other juniors, however it appears that the fundamentals are better than ever.  Always do your own DD...

<< Previous
Bullboard Posts
Next >>